D
David S. Reynolds
Researcher at Merck & Co.
Publications - 43
Citations - 3447
David S. Reynolds is an academic researcher from Merck & Co.. The author has contributed to research in topics: GABAA receptor & Receptor. The author has an hindex of 24, co-authored 42 publications receiving 3272 citations. Previous affiliations of David S. Reynolds include Lundbeck & Pfizer.
Papers
More filters
Journal ArticleDOI
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.
Ruth M. McKernan,Thomas W. Rosahl,David S. Reynolds,Cyrille Sur,Keith A. Wafford,John R. Atack,Sophie J. Farrar,J Myers,G.P. Cook,Pushpinder Ferris,L Garrett,Linda J. Bristow,George R. Marshall,Alison J. Macaulay,N. Brown,Owain W. Howell,Kevin W. Moore,Robert W. Carling,Leslie J. Street,Castro Jl,C.I. Ragan,G. R. Dawson,Paul J. Whiting +22 more
TL;DR: This work created genetically modified mice with a diazepam-insensitive α1 subtype and a selective BZ site ligand to explore GABAA receptor subtypes mediating specific physiological effects and revealed that the α1Subtype mediated the sedative, but not the anxiolytic effects of benzodiazepines.
Journal ArticleDOI
Sedation and Anesthesia Mediated by Distinct GABAA Receptor Isoforms
David S. Reynolds,Thomas W. Rosahl,Jennifer Cirone,Gillian F. O'Meara,Alison R. Haythornthwaite,Richard J. Newman,J Myers,Cyrille Sur,Owain W. Howell,A. Richard Rutter,John R. Atack,Alison J. Macaulay,K. L. Hadingham,Peter H. Hutson,Delia Belelli,Jeremy J. Lambert,Gerard R. Dawson,Ruth M. McKernan,Paul J. Whiting,Keith A. Wafford +19 more
TL;DR: Findings show that anesthesia and sedation are mediated by distinct GABAA receptor subtypes, and that the β2 subunit mediates the sedative properties of anesthetics.
Journal ArticleDOI
Evidence for a Significant Role of α3-Containing GABAA Receptors in Mediating the Anxiolytic Effects of Benzodiazepines
Rebecca Dias,Wayne F. A. Sheppard,Rosa L. Fradley,Elizabeth M. Garrett,Joanna Stanley,Spencer J. Tye,Simon Charles Goodacre,Rachael Lincoln,Susan M. Cook,Rachel K. Conley,David James Hallett,Alexander Charles Humphries,Sally A. Thompson,Keith A. Wafford,Leslie J. Street,J. Luis Castro,Paul J. Whiting,Thomas W. Rosahl,John R. Atack,Ruth M. McKernan,Gerard R. Dawson,David S. Reynolds +21 more
TL;DR: Data show that potentiation of α3-containing GABAA receptors is sufficient to produce the anxiolytic effects of BZs and that α2 potentiation may not be necessary.
Journal ArticleDOI
Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice.
Cyrille Sur,Keith A. Wafford,David S. Reynolds,K. L. Hadingham,Frances A. Bromidge,Alison J. Macaulay,Neil Collinson,Gillian F. O'Meara,Owain W. Howell,Richard J. Newman,J Myers,John R. Atack,Gerard R. Dawson,Ruth M. McKernan,Paul J. Whiting,Thomas W. Rosahl +15 more
TL;DR: It is confirmed that α1β2γ2 is the major GABAA receptor subtype in the murine brain and it is demonstrated that, surprisingly, the loss of this receptor sub type is not lethal.
Journal ArticleDOI
An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
Gerard R. Dawson,Karen A. Maubach,Neil Collinson,M. Cobain,B. J. Everitt,Angus Murray Macleod,Hedaythul Choudhury,L. M. McDonald,Goplan V. Pillai,W. Rycroft,Alison J. Smith,F. Sternfeld,F. D. Tattersall,Keith A. Wafford,David S. Reynolds,Guy R. Seabrook,John R. Atack +16 more
TL;DR: The 5-subunit GABAA receptor was found to be a novel target for the development of selective inverse agonists with utility in the treatment of disorders associated with a cognitive deficit as mentioned in this paper.